

K062796

## (Appendix A)

### 510(k) Summary of Safety and Effectiveness

DEC - 8 2006

---

**Submitter** Personal Products Company  
Division of McNeil – PPC, Inc.  
199 Grandview Road  
Skillman, NJ 08558

---

**Contact** Nader Fotouhi, Ph.D.  
Manager, Regulatory Affairs  
Personal Product Company  
Division of McNeil – PPC, Inc.  
199 Grandview Road  
Skillman, NJ 08558

Phone: (908) 904-3730  
Fax: (908) 904-3748

---

**Date** September 15, 2006

---

**Trade Name** K-Y® Brand Intrigue™

---

**Common Name** Personal Lubricant

---

**Classification Name** HIS - Condom (21CFR 884.5300)  
MMS - Patient Lubricant (21CFR 880.6375)

---

**Statement** This proposed device is substantially equivalent to currently marketed predicate device, K-Y® Brand ULTRA GEL™.

---

**Device description** This device is a personal lubricant compatible with latex condom.

---

[INFORMATION IN BRACKETS IS CONSIDERED CONFIDENTIAL]



## DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
9200 Corporate Blvd.  
Rockville MD 20850

Nader Fotouhi, Ph.D.  
Manager, Regulatory Affairs  
Personal Products Company  
Division of McNeil-PPC, Inc.  
199 Grandview Road  
SKILLMAN NJ 08558-9418

DEC 8 2006

Re: K062796

Trade/Device Name: K-Y® Brand Intrigue™  
Regulation Number: 21 CFR §884.5300  
Regulation Name: Condom  
Regulatory Class: II  
Product Code: NUC  
Dated: September 15, 2006  
Received: September 19, 2006

Dear Dr. Fotouhi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



*Protecting and Promoting Public Health*

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 894.xxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

## (Appendix C)

### Indications for Use Statement

---

510(k) Number, if known

K062796

---

Device Name: K-Y® Brand Intrigue™

Indications for Use:

K-Y® Brand Intrigue™ is intended as a personal lubricant for penile and vaginal application compatible with latex condom.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use \_\_\_\_\_ OR Over-the-Counter Use  \_\_\_\_\_

Nancy C. Brogdon  
(Division Sign-Off)  
Division of Reproductive, Abdominal, and  
Radiological Devices  
510(k) Number K062796

[INFORMATION IN BRACKETS IS CONSIDERED CONFIDENTIAL]